Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
November 01, 2024 12:30 ET
|
Zealand Pharma
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1,...
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
October 08, 2024 18:45 ET
|
Zealand Pharma
Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response...
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
October 08, 2024 02:40 ET
|
Zealand Pharma
Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide ...
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
September 30, 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
September 13, 2024 11:01 ET
|
Zealand Pharma
Press Release – No. 9 / 2024 Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Copenhagen, Denmark, September 13, 2024 – Zealand Pharma A/S...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
September 12, 2024 11:01 ET
|
Zealand Pharma
Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S...
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
September 09, 2024 11:01 ET
|
Zealand Pharma
Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
August 30, 2024 16:00 ET
|
Zealand Pharma
Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
August 30, 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Copenhagen, Denmark, August 30, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
August 22, 2024 16:00 ET
|
Zealand Pharma
Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 22, 2024 – Zealand Pharma A/S...